Bellerophon Therapeutics Price To Book vs. Cash Per Share
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
For Bellerophon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bellerophon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bellerophon Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bellerophon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bellerophon Therapeutics over time as well as its relative position and ranking within its peers.
Bellerophon |
Bellerophon Therapeutics Cash Per Share vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Bellerophon Therapeutics's current stock value. Our valuation model uses many indicators to compare Bellerophon Therapeutics value to that of its competitors to determine the firm's financial worth. Bellerophon Therapeutics is rated fifth in price to book category among its peers. It is rated below average in cash per share category among its peers fabricating about 1.62 of Cash Per Share per Price To Book. Comparative valuation analysis is a catch-all model that can be used if you cannot value Bellerophon Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bellerophon Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bellerophon Cash Per Share vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Bellerophon Therapeutics |
| = | 1.05 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Bellerophon Therapeutics |
| = | 1.71 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Bellerophon Cash Per Share Comparison
Bellerophon Therapeutics is currently under evaluation in cash per share category among its peers.
Bellerophon Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Bellerophon Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bellerophon Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bellerophon Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Bellerophon Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.
Bellerophon Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Bellerophon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bellerophon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bellerophon Therapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Bellerophon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Use Investing Themes to Complement your Bellerophon Therapeutics position
In addition to having Bellerophon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |